MTx is an innovator in the field of antibody discovery and immune repertoire analysis. Our antibody discovery platform DROPZYLLA® uses robust, simple, and fast microfluidic single-cell technologies to enable antibody repertoire mining and mAb discovery at unprecedented efficiency and speed.

Products, services, technology

The company’s current pipeline features programs in transplant virology and immuno-oncology. mAb “AntiBKV” is currently in clinical development for the treatment of BK polyomavirus infection in kidney transplant recipients.

Cooperation possibilities

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery from human and animal species across all indications for proprietary and partnered projects.



Wagistrasse 27, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business